EMEA-000380-PIP08-21
Key facts
Invented name |
Cosentyx
|
Active substance |
Secukinumab
|
Therapeutic area |
Immunology-Rheumatology-Transplantation
|
Decision number |
P/0560/2021
|
PIP number |
EMEA-000380-PIP08-21
|
Pharmaceutical form(s) |
|
Condition(s) / indication(s) |
Treatment of vasculitides
|
Route(s) of administration |
Subcutaneous use
|
Contact for public enquiries |
Novartis Europharm Limited
E-mail: paediatric.enquiries@novartis.com |
Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|